Henri Stalder

1.1k total citations
23 papers, 570 citations indexed

About

Henri Stalder is a scholar working on Molecular Biology, Organic Chemistry and Pharmacology. According to data from OpenAlex, Henri Stalder has authored 23 papers receiving a total of 570 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 5 papers in Organic Chemistry and 5 papers in Pharmacology. Recurrent topics in Henri Stalder's work include Receptor Mechanisms and Signaling (5 papers), Amino Acid Enzymes and Metabolism (3 papers) and Pharmacology and Obesity Treatment (3 papers). Henri Stalder is often cited by papers focused on Receptor Mechanisms and Signaling (5 papers), Amino Acid Enzymes and Metabolism (3 papers) and Pharmacology and Obesity Treatment (3 papers). Henri Stalder collaborates with scholars based in Switzerland and France. Henri Stalder's co-authors include Roger D. Norcross, Marius C. Hoener, Laurence Ozmen, Amyaouch Bradaïa, Joseph G. Wettstein, Bernhard Bettler, Gerhard Trube, Gottfried Oesterhelt, Martin Gassmann and Emmanuel Pinard and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Medicinal Chemistry and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Henri Stalder

23 papers receiving 549 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Henri Stalder Switzerland 14 306 243 115 110 51 23 570
Alejandra Gallardo‐Godoy United States 15 345 1.1× 119 0.5× 245 2.1× 80 0.7× 88 1.7× 17 743
Tadeusz Karcz Poland 20 492 1.6× 174 0.7× 339 2.9× 157 1.4× 25 0.5× 63 959
Kristin M. Rusche United States 10 360 1.2× 189 0.8× 132 1.1× 55 0.5× 76 1.5× 10 1.0k
Yasuchika Yamaguchi Japan 16 346 1.1× 181 0.7× 216 1.9× 39 0.4× 25 0.5× 26 762
Mark P. Wentland United States 22 640 2.1× 346 1.4× 486 4.2× 165 1.5× 28 0.5× 68 1.2k
Agnieszka Olejarz‐Maciej Poland 15 257 0.8× 86 0.4× 179 1.6× 99 0.9× 31 0.6× 34 515
Eric A. Ertel Switzerland 17 620 2.0× 312 1.3× 117 1.0× 51 0.5× 20 0.4× 29 905
Jeffrey M. Schkeryantz United States 19 448 1.5× 109 0.4× 642 5.6× 127 1.2× 24 0.5× 30 1.1k
Walter A. Escobar United States 7 252 0.8× 156 0.6× 28 0.2× 78 0.7× 200 3.9× 10 484
James R. Blinn United States 11 426 1.4× 214 0.9× 123 1.1× 74 0.7× 44 0.9× 16 920

Countries citing papers authored by Henri Stalder

Since Specialization
Citations

This map shows the geographic impact of Henri Stalder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henri Stalder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henri Stalder more than expected).

Fields of papers citing papers by Henri Stalder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henri Stalder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henri Stalder. The network helps show where Henri Stalder may publish in the future.

Co-authorship network of co-authors of Henri Stalder

This figure shows the co-authorship network connecting the top 25 collaborators of Henri Stalder. A scholar is included among the top collaborators of Henri Stalder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henri Stalder. Henri Stalder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schnider, Patrick, Henri Stalder, Rainer E. Martin, et al.. (2019). Modulation of Pharmacologically Relevant Properties of Piperidine Derivatives by Functional Groups in an Equatorial or Axial β‐Position to the Amino Group. ChemBioChem. 21(1-2). 212–234. 8 indexed citations
2.
Pinard, Emmanuel, Daniela Alberati, Rubén Alvarez‐Sánchez, et al.. (2014). 3-Amido-3-aryl-piperidines: A Novel Class of Potent, Selective, and Orally Active GlyT1 Inhibitors. ACS Medicinal Chemistry Letters. 5(4). 428–433. 5 indexed citations
3.
Galley, Guido, et al.. (2012). Optimisation of imidazole compounds as selective TAAR1 agonists: Discovery of RO5073012. Bioorganic & Medicinal Chemistry Letters. 22(16). 5244–5248. 46 indexed citations
4.
Galley, Guido, et al.. (2012). ChemInform Abstract: Optimization of Imidazole Compounds as Selective TAAR1 Agonists: Discovery of RO5073012.. ChemInform. 43(48). 2 indexed citations
5.
Stalder, Henri, Marius C. Hoener, & Roger D. Norcross. (2010). Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): Discovery of EPPTB (RO5212773). Bioorganic & Medicinal Chemistry Letters. 21(4). 1227–1231. 47 indexed citations
6.
Bradaïa, Amyaouch, Gerhard Trube, Henri Stalder, et al.. (2009). The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proceedings of the National Academy of Sciences. 106(47). 20081–20086. 181 indexed citations
7.
Bradaïa, Amyaouch, Gerhard Trube, Henri Stalder, et al.. (2009). P.l.c.038 Modulation of dopaminergic activity in the mesolimbic system by trace amine-associated receptor 1 (TAAR1) modification. European Neuropsychopharmacology. 19. S273–S273. 1 indexed citations
8.
Pinard, Emmanuel, Daniela Alberati, Edilio Borroni, et al.. (2008). Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(18). 5134–5139. 18 indexed citations
9.
Alberati, Daniela, Simona Ceccarelli, Synèse Jolidon, et al.. (2006). Design and synthesis of 4-substituted-8-(2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of GlyT1 inhibitors: Achieving selectivity against the μ opioid and nociceptin/orphanin FQ peptide (NOP) receptors. Bioorganic & Medicinal Chemistry Letters. 16(16). 4305–4310. 11 indexed citations
10.
Pinard, Emmanuel, Simona Ceccarelli, Henri Stalder, & Daniela Alberati. (2005). Discovery of N-(2-aryl-cyclohexyl) substituted spiropiperidines as a novel class of GlyT1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(2). 349–353. 19 indexed citations
11.
Ceccarelli, Simona, Emmanuel Pinard, Henri Stalder, & Daniela Alberati. (2005). Discovery of N-(2-hydroxy-2-aryl-cyclohexyl) substituted spiropiperidines as GlyT1 antagonists with improved pharmacological profile. Bioorganic & Medicinal Chemistry Letters. 16(2). 354–357. 19 indexed citations
12.
Dourish, Colin T., Adams, Karen Benwell, et al.. (2004). Discovery and development of selective 5-HT2C receptor agonists for obesity. Fundamental and Clinical Pharmacology. 18. 127–127. 2 indexed citations
13.
Apfel, Christian, David W. Banner, Daniel Bur, et al.. (2001). 2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-Dioxo-1,4-dihydro-2H-2λ6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as Potent and Selective Peptide Deformylase Inhibitors. Journal of Medicinal Chemistry. 44(12). 1847–1852. 31 indexed citations
14.
Stalder, Henri, et al.. (1992). ChemInform Abstract: Tetrahydrolipstatin: Degradation Products Produced by Human Carboxyl‐ Ester Lipase.. ChemInform. 23(48). 1 indexed citations
15.
Stalder, Henri, Gottfried Oesterhelt, & Bengt Borgström. (1992). Tetrahydrolipstatin: Degradation products produced by human carboxyl‐ester lipase. Helvetica Chimica Acta. 75(5). 1593–1603. 26 indexed citations
16.
Stalder, Henri, et al.. (1990). Tetrahydrolipstatin: Thermal and Hydrolytic Degradation. Helvetica Chimica Acta. 73(4). 1022–1036. 20 indexed citations
17.
Folláth, Ferenc, et al.. (1986). Use of ciprofloxacin in the treatment ofPseudomonas aeruginosa infections. European Journal of Clinical Microbiology & Infectious Diseases. 5(2). 236–240. 57 indexed citations
18.
Francioli, P, M.G. Clement, Stefanos Geroulanos, et al.. (1983). Ceftazidime in severe infections: a Swiss multicentre study. Journal of Antimicrobial Chemotherapy. 12(suppl A). 139–146. 22 indexed citations
19.
Schiess, Peter & Henri Stalder. (1980). Aromatisation of 3-carbomethoxy-3-methyl-3h-pyrazol solvent effect and catalysis through acid. Tetrahedron Letters. 21(15). 1413–1416. 13 indexed citations
20.
Stalder, Henri, et al.. (1980). Migration tendencies of functional groups toward sigmatropic rearrangement in 3,3-disubstituted 3H-pyrazoles. Tetrahedron Letters. 21(15). 1417–1420. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alejandra Gallardo‐Godoy Breakdown of academic impact, for papers by Tadeusz Karcz Breakdown of academic impact, for papers by Kristin M. Rusche Breakdown of academic impact, for papers by Yasuchika Yamaguchi Breakdown of academic impact, for papers by Mark P. Wentland Breakdown of academic impact, for papers by Agnieszka Olejarz‐Maciej Breakdown of academic impact, for papers by Eric A. Ertel Breakdown of academic impact, for papers by Jeffrey M. Schkeryantz Breakdown of academic impact, for papers by Walter A. Escobar Breakdown of academic impact, for papers by James R. Blinn
Rankless by CCL
2026